Brenner 1-3 Brenner
(subtype) .4-6
, ,
.7-9 38
1 .
, 38 ,
2001 12 18
14 , 30
, 3-4
.
2001 11 25 .
2-0-2-2
.
, 2000 5
. 2
Department of Obstetrics and Gynecology, Pathology, Dankook University College of Medicine, Cheonan, Korea
Primary transitional cell carcinoma of the ovary has been only recently recognized, as one of the main types of ovarian carcinoma because of the favorable response to chemotherapy and improved survival of the patient. Histologically, it is distinguished from malignant Brenner tumor only in the absence of benign or proliferative Brenner tumor component.
Recent histopathologic reports show that transitional cell carcinoma of the bladder and of the ovary are immunophenotypically different. Primary transitional cell carcinomas are more aggressive than malignant Brenner tumor.
However, primary transitional cell carcinomas have a better response to chemotherapy than other types of ovarian carcinomas.
We have experienced a very rare case of primary papillary transitional cell carcinoma of the left ovary in a 38-year-old woman and report it with review of literatures.
Key Words : Ovary, Papillary transitional cell carcinoma
.
, 165 cm, 64 kg, 130/80 mmHg,
90/min, 24/min , 37.0
. ,
, .
. 12.5 g/
dl, 37%, 7,240/mm3,
336,000/mm3, HBsAg , HBsAb , VDRL
, ,
, , , X
EKG .
CA-125 128.77 U/ml
CEA CA 19-9 8.69 ng/ml, 1.50
U/ml . 7×4×3
cm , 6.2×8.2 cm
. , S
,
, .
.
8.6
cm (lobulated margin)
,
,
(Fig. 1 and Fig. 2).
10 3
.
. S
, .
.
, ,
.
10.6×8.2
×3.5 cm 470 gm .
, (Fig. 3).
, . , . transitional cell carcinoma
tumor cell nest .
,
serous carcinoma .
(Fig. 4).
,
transitional cell carcinoma (Fig. 5).
,
. 4
, (Cisplatin)
13
. Taxol 6
Taxol-Carboplatin
4 . CA 125
2003 1 7.22 U/ml , 2002
11 4 CT CT
,
.
2003 3 , .
.
cell carcinoma)
.
1% .6
Brenner , ,
1987 Austin Norris4 Brenner
.5 Brenner
Brenner
Brenner grade 2 3
.4,6 , Brenner Brenner
. Brenner
(stromal calcification) . Young Scully10
. ,
, 20%
.4
39 78 50
. Silva 6 M. D. Anderson
10 Mexico
20 11 1
. 12(1997) 2 ,
13(1993) 2 , 14(2000) 1 , 15(2001)
1 .
.
.
(chromatin) 2
3 .
.
Wick 16 1985
.
. . Ordonez17
.
(urothelium) (surface
glycoprotein) thrombomodulin (TM) cytokine 20, carcinoembryonic antigen (CEA)
TM cytokine 20
CEA 13
TM cytokine 20
CEA 2
.
.
Brenner , ,
, .6
Austin Norris4
. Brenner
.
.4
hexamethylmelamine-doxorubicin-cyclophosphamide, mephalan-cisplatin, mephalan, cisplatin-doxorubicin- cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin-cyclophosphamide .3 Maluf Bajorin18
CISCA (cyclophosphamide, doxorubicin, and cisplatin), CMV (cisplatin, methotrexate, and vinblastine), M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) , docetaxel, paclitaxel, gemcitabine, ifosfamide
. Sweeten 19
(refractory transitional cell carcinoma) (salvage chemotherapy)
.
.
, (endometrioid)
.5,6 Gershenson 7 Sweeten 19
. Silva
6
. Robey 5 1989 9
7
(aneuploid) 2 (diploid) 4
(tetraploid) 1 7
2
. 1992 Martin 20
3 1
. (disseminated carcinomatosis)
.4 38
1
.
(subtype) .
. ,
. 38 1
. ,